Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AYTU vs TKNO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AYTU Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–4 Matrix Metrics)

AYTU Overall Winner 6-Pillar Tally: AYTU 4 – 1 TKNO (1 Tie) Matrix Metrics: AYTU 6 – 4 TKNO

As of Nov 16, 2026, AYTU BioPharma, Inc. (AYTU) is the stronger overall head-to-head candidate over Alpha Teknova, Inc. (TKNO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). AYTU carries a Unified Composite Score of 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin), whereas TKNO carries 37.6/100 (SELL) at $7.90 (N/M Forward P/E, -31.6% operating margin).

  • Growth vs. Quality Trade-Off: AYTU earns the overall head-to-head edge with a stronger Unified Composite Score (48.9/100 HOLD vs. TKNO 37.6/100 SELL) and 0.65β · 35% Vol risk profile, whereas TKNO leads top-line expansion (+21.5% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: AYTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile TKNO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 50.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AYTU vs TKNO
AYTU NASDAQ Head-to-Head Winner
AYTU BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$1.81
+1.69% 1D
Market Cap $19.6M
TTM Revenue $58M
Forward P/E 9.2x
Beta / 30D Vol 0.65β · 35% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 49.0 Fund 53.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.8%), weak momentum, RSI 38
RSI-14: 37.7 · SMA20: $1.89 · SMA50: $2.00
TKNO NASDAQ
Alpha Teknova, Inc. Common Stock
In Vitro & In Vivo Diagnostic Substances
$7.90
-3.78% 1D
Market Cap $521.8M
TTM Revenue $46M
Forward P/E N/M
Beta / 30D Vol 1.19β · 114% Vol
Unified Composite Score
37.6 / 100 SELL
Tech 5.0 Fund 33.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.8% over 20 days), RSI 51
RSI-14: 50.8 · SMA20: $7.53 · SMA50: $7.87

6-Pillar Scorecard Institutional Category Breakdown (AYTU 4 – 1 TKNO)

Columns: Metric · AYTU · TKNO
1. Valuation Multiples AYTU
Forward P/E 9.2x N/M
Trailing P/E 9.2x N/M
PEG Ratio N/M N/M
EV / Revenue 0.3x 11.4x
2. Growth & Scale TKNO
Revenue Growth (YoY) +6.4% +21.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $58M $46M
Market Cap $19.6M $521.8M
3. Profitability & Quality AYTU
Gross Margin 64.0% 36.4%
Operating Margin -14.4% -31.6%
Net Profit Margin -24.8% -34.8%
Return on Equity (ROE) -52.5% -24.1%
4. Balance Sheet & Cash Flow AYTU
Cash Generation (TTM) -$1.4M -$8.2M EBITDA
Cash Flow Margin -2.4% -17.8% EBITDA Mgn
Net Cash / Leverage $4.9M Net Cash $1.11 Book/Sh · -24.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 10.6% (<1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat AYTU
OpEx & R&D Intensity 78.4% of Rev ($45M) 68.0% of Rev ($31M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AYTU (6) vs TKNO (4)
Institutional Metric AYTU TKNO Criterion Row Edge
Market Capitalization
Scale
$19.6M $521.8M Larger Scale TKNO
Trailing P/E Ratio
Valuation
9.2x N/M Lower Multiple AYTU
Forward P/E Ratio
Valuation
9.2x N/M Lower Multiple AYTU
Revenue Growth (YoY)
Growth
+6.4% +21.5% Higher Growth TKNO
Operating Margin (TTM)
Profitability
-14.4% -31.6% Higher Margin AYTU
Net Profit Margin
Profitability
-24.8% -34.8% Higher Margin AYTU
Return on Equity (ROE)
Capital Efficiency
-52.5% -24.1% Higher ROE TKNO
52-Week Range Position
Momentum
5% ($2–$3) 79% ($2–$9) Stronger Trend TKNO
Beta / 30D Volatility
Risk Regime
0.65β · 35% Vol 1.19β · 114% Vol Lower Realized Risk AYTU
Unified Institutional Score
Composite Signal
48.9 / 100 (HOLD) 37.6 / 100 (SELL) Higher Composite AYTU
Trailing 12M Revenue (USD)
Operating Scale
$58M $46M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
64.0% 36.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.3x EV/Rev N/M PEG · 11.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$1.4M ($4.9M Net Cash) -$8.2M EBITDA ($1.11 Book/Sh · -24.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TKNO +22.85 pp
AYTU: -11.27% · TKNO: +11.58%
3M Horizon TKNO +39.32 pp
AYTU: -23.31% · TKNO: +16.01%
6M Horizon TKNO +132.04 pp
AYTU: -13.81% · TKNO: +118.23%
1Y Horizon TKNO +90.47 pp
AYTU: -12.14% · TKNO: +78.33%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AYTU vs TKNO. Trailing 12-month operating profitability (AYTU -14.4% vs TKNO -31.6%) and valuation multiples (AYTU 9.2x vs TKNO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AYTU ADR TTM Benchmark FX-Normalized USD
TTM Revenue$58M
Gross Margin64.0%
Op. Margin-14.4%
ROE / Fwd P/E-52.5% · 9.2x
TKNO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$46M
Gross Margin36.4%
Op. Margin-31.6%
ROE / Fwd P/E-24.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AYTU UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AYTU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TKNO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 10.6%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TKNO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AYTU Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $19.6M market capitalization and -14.4% operating margin.
OpEx & R&D Reinvestment 78.4% of Rev ($45M)
90D Engineering Disclosures 0 Published
TKNO Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $521.8M market capitalization and -31.6% operating margin.
OpEx & R&D Reinvestment 68.0% of Rev ($31M)
90D Engineering Disclosures 0 Published

Investor FAQ AYTU vs TKNO Key Questions & Quantitative Answers

As of Nov 16, 2026, AYTU BioPharma, Inc. (AYTU) is the stronger overall head-to-head candidate over Alpha Teknova, Inc. (TKNO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). AYTU carries a Unified Composite Score of 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin), whereas TKNO carries 37.6/100 (SELL) at $7.90 (N/M Forward P/E, -31.6% operating margin). Growth vs. Quality Trade-Off: AYTU earns the overall head-to-head edge with a stronger Unified Composite Score (48.9/100 HOLD vs. TKNO 37.6/100 SELL) and 0.65β · 35% Vol risk profile, whereas TKNO leads top-line expansion (+21.5% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: AYTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile TKNO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 50.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TKNO leads the Growth & Scale pillar: AYTU posts +6.4% YoY revenue growth and +0.0% YoY earnings growth on $58M TTM revenue (64.0% gross margin, -14.4% operating margin), compared with TKNO at +21.5% YoY revenue growth and +0.0% YoY earnings growth on $46M TTM revenue (36.4% gross margin, -31.6% operating margin). On trailing 12-month operating scale, AYTU generates $58M in USD-normalized revenue versus $46M for TKNO. In operating R&D and SG&A reinvestment, AYTU deploys 78.4% of Rev ($45M) (0 90-day corporate R&D disclosures) versus 68.0% of Rev ($31M) (0 disclosures) for TKNO.

AYTU screens cheaper on headline valuation multiples. AYTU trades at 9.2x Forward P/E, 9.2x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-2.4% FCF margin), whereas TKNO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 11.4x EV/Revenue (-17.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AYTU (-52.5% ROE) versus TKNO (-24.1% ROE) capital efficiency.

In options market volatility and institutional positioning, AYTU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 35% Vol realized risk). By comparison, TKNO carries 10.6% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 114% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.